Improving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial

Size: px
Start display at page:

Download "Improving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial"

Transcription

1 Improving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial Robert James Cerfolio, MD, FACS, Ayesha S. Bryant, MD, MSPH, Buddhiwardhan Ojha, MD, MPH, and Mohammad Eloubeidi, MD Section of Thoracic Surgery, University of Alabama at Birmingham and Division of Cardiothoracic Surgery, Department of Surgery, Birmingham Veterans Administration Hospital, Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Divisions of Nuclear Radiology and Gastroenterology, University of Alabama at Birmingham, Birmingham, Alabama GENERAL THORACIC Background. Clinical stage affects the care of patients with nonsmall cell lung cancer. Methods. This is a prospective trial on patients with suspected resectable nonsmall cell lung cancer. All patients underwent integrated positron emission tomographic scanning and computed tomographic scanning, and all suspicious metastatic sites were investigated. A, T, N, and M status was assigned. If N2, N3 and M1 were negative, patients underwent thoracotomy and complete thoracic lymphadenectomy. Results. There were 383 patients. The accuracy of clinical staging using positron emission tomographic scanning and computed tomographic scanning was 68% and 66% for stage I, 84% and 82% for stage II, 74% and 69% for stage III, and 93% and 92% for stage IV, respectively. N2 disease was discovered in 115 patients (30%) and was most common in the subcarinal lymph node (30%). Unsuspected N2 disease occurred in 28 patients (14%) and was most common in the posterior mediastinal lymph nodes (subcarinal, 38%; posterior aortopulmonary, 15%). It was found in 9% of patients who were clinically staged I (58% in the posterior mediastinal lymph nodes) and in 26% of patients clinically staged II (86% in posterior mediastinal lymph nodes). Conclusions. Despite integrated positron emission tomographic scanning and computed tomographic scanning, clinical staging remains relatively inaccurate for patients with nonsmall cell lung cancer. Recent studies suggest adjuvant therapy for stage Ib and II nonsmall cell lung cancer; thus the impact on preoperative care is to find unsuspected N2 disease. Unsuspected N2 disease is most common in posterior mediastinal lymph nodes inaccessible by mediastinoscopy. Thus one should consider endoscopic ultrasound fine-needle aspiration, especially for patients clinically staged as I and II, even if the nodes are negative on positron emission tomographic scanning and computed tomographic scanning. (Ann Thorac Surg 2005;80: ) 2005 by The Society of Thoracic Surgeons Lung cancer is responsible for more cancer deaths than the next three most common cancers combined. In particular, nonsmall cell lung cancer (NSCLC) accounts for approximately 75% to 85% of all newly diagnosed lung cancers [1]. Treatment of NSCLC depends on stage. The best tests for assessing the clinical stage are the computed tomographic (CT) scan and dedicated positron emission tomographic (PET) scan using 2-dexoy-2-18F flouro-d-glucose (FDG-PET). These tests often detect suspicious areas of metastases that should be further investigated with other tests such as a bone scan, ultrasound, and magnetic resonance imaging. Procedures that biopsy these sites, such as mediastinoscopy, endoscopic ultrasound fine-needle aspiration (EUS-FNA) and ultrasound-guided biopsy of the liver are mandatory. However, despite all these sophisticated tests and even the use of integrated scanning, Accepted for publication April 5, Presented at the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 24 26, Address reprint requests to Dr Cerfolio, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL 35294; robert.cerfolio@ccc.uab.edu. which we have shown to be superior to dedicated FDG- PET scanning in the staging of patients with NSCLC [2], the pathologic stage often differs from the predicted clinical stage [2 5]. We decided to prospectively assess the accuracy of the predicted clinical stage and compare it with the actual pathologic stage; we also wanted to see at which stage it most commonly fails. We specifically addressed each separate lymph node station and assessed how many patients could have their care improved by having more accurate clinically staging. Until the ongoing studies that examine the use of neoadjuvant therapy for the early stages of NSCLC (ie, stages Ib and II) are completed, the current standard of care is to use surgical resection followed by adjuvant chemotherapy. Thus, for now it is only the discovery of unsuspected N2 or M1 disease that alters preoperative treatment. The EUS-FNA is a noninvasive procedure that affords biopsies of posterior mediastinal (N2) lymph nodes at locations 5, 7, 8, and 9 [6]. It is highly accurate in these nodal stations [7, 8]. We also evaluated the potential impact that the EUS-FNA would have if it had been performed on all patients prior to pulmonary resection by The Society of Thoracic Surgeons /05/$30.00 Published by Elsevier Inc doi: /j.athoracsur

2 GENERAL THORACIC 1208 CERFOLIO ET AL Ann Thorac Surg IMPROVING CLINICAL STAGING OF NSCLC 2005;80: Patients and Methods Patient Selection Patients who presented to one surgeon (RJC) between September 2002 and August 1, 2004 with an indeterminate pulmonary nodule or a biopsy proven NSCLC and underwent integrated scanning at our institution and CT scanning were eligible to participate in this study. Patients were excluded if they were less than 19 years of age, had a history of type I diabetes, or received preoperative chemotherapy or radiation. All patients were clinically staged using the T, N, and M classification system [9]. A stage was given for each patient based on the scan, which was read by a nuclear radiologist, and based on the CT scan, which as read by a chest radiologist. Radiologic Imaging The scans were performed on an integrated PET/CT scanner (GE Discovery LS PET/CT Scanner, Milwaukee, WI). Patients were asked to fast for 4 hours and then subsequently received 555 MBq (15mCi) of FDG intravenously followed by PET scanning after 1 hour. The scans were performed from the skull base to mid-thigh level. The computed tomography examination was used for attenuation correction of PET images. The scanning time for positron emission tomography was 5 minutes per bed position. Iterative reconstruction with CT attenuation correction was performed. The most recent CT scan of the chest was also available for visual correlation. Maximum standard uptake value (maxsuv) of the primary lymph node and of each suspicious lymph node station was determined by drawing regions of interest on the attenuation corrected images around it. It was then calculated by the software contained within the PET or PET/CT scanner by the formula [10]: C( Ci ml) maxsuv ID( Ci) w(kg) in which C activity at a pixel within the tissue defined by the regions of interest, and ID injected dose per kg of patients body weight (w). The maximum standard uptake value (maxsuv) within the selected regions of interest was used exclusively throughout this study. Procedures, Staging, and Surgery Patients were meticulously staged. All suspicious N2, N3, or M1 areas (maxsuv 2.5) were biopsied prior to pulmonary resection. Mediastinoscopy was used to biopsy suspicious lymph nodes in the paratracheal area (stations 2R, 4R, 2L, and 4L), and endoscopic transesophageal ultrasound was used to biopsy suspicious posterior aorta-pulmonary window nodes (5), subcarinal (7), periesophageal (8) and inferior pulmonary ligament nodes (9). Endoscopic ultrasound (EUS) was performed under conscious sedation as previously described [7], and these were all performed by a single experienced endosonographer (MAE) ( 2,500 EUS procedures). A radial echoendoscope (GF-UM130 [Olympus America, Melville, NY]) was first used to evaluate the presence or absence of a lymphadenopathy. Once a suspicious lymph node was identified (the endosonographic criteria for malignant lymph node involvement was previously described [11]), the radial echoendoscope was removed and a curvilinear echoendoscope (Olympus UC-30P or UCT 140, Melville, NY) was inserted. The EUS-FNA of the target lesions by the PET/CT scans and the CT scans was performed as previously described [12]. EUS-FNAs were preformed using a 22-gauge adjustable length Echotip needle (Wilson-Cook Inc, Winston Salem, NC). Cytological diagnosis of the aspirated lesion was reported as either positive for metastatic cancer or negative. The endosonographer (MAE) was blinded to the CT scan report and to the scan report. In general, nodes targeted as abnormal by these modalities were biopsied, but if they could not be located by EUS, then they were not biopsied. Patients with suspected M1 disease in the liver, adrenal, or contralateral lung underwent definitive biopsy to prove or disprove M1 cancer. If the bone or brain was suspected to harbor metastases, magnetic resonance imaging was considered the standard reference. If patients had biopsy proven N3 or M1 disease the stage was recorded but they were not resected. If there was no evidence of N2 or higher disease, patients underwent thoracotomy, pulmonary resection, and complete thoracic lymphadenectomy. Pathologic review was performed by standard techniques and immunohistochemical staining was used when appropriate. The pathologic stage was assessed using the international staging system [9]. A patient was defined as having unsuspected N2 disease if neither the scan nor the CT scan suggested any cancer in any of the N2 nodes (clinically called N2 negative) but the patient had pathologic proof of metastatic NSCLC cancer in at least one N2 node. The University of Alabama at Birmingham s institutional review board approved both this prospective trial and the electronic prospective database used for this study. Statistical Methods Data was stored using an Access database (Microsoft, Seattle, WA) and analyzed using EpiInfo (Centers for Disease Control, Atlanta, GA) and the SAS program, version 9.0 (SAS, Cary, NC). Efficacy (ie, sensitivity, specificity, positive predicted value, negative predicted value and accuracy) was determined for CT scanning and scanning using the pathology or biopsy results as the gold standard. Standard definitions were used to calculate these parameters [13]. Table 1 depicts how the true positives, true negatives, false positives, and false negatives for the clinical stage were defined for calculation of the efficacy. It also shows how the percentage for unsuspected N2 disease was calculated. The binomial approximation test was used to compare efficacy.

3 Ann Thorac Surg CERFOLIO ET AL 2005;80: IMPROVING CLINICAL STAGING OF NSCLC Table 1. Definition of Variables Used to Compute Efficacy of Clinical Stage (An Example Is Given for Patients Clinically Staged as Stage I) Pathology Pathology Clinical stage True positive (TP) False positive (FP) Pathological stage equals clinical stage Pathological stage is any other than the clinically stage predicted Example: Example: Pathology stage I Pathology stage II, III, or IV Clinical stage I Clinical stage I Clinical stage False negative (FN) True negative (TN) The pathological stage is the one predicted, but the clinical stage is all other stages Example: Pathology stage I Clinical stage II, III, or IV 1209 Neither the pathological nor the clinical stage is the one predicted Example: Pathology stage II, III, or IV Clinical stage II, III, or IV GENERAL THORACIC TP TN TP Sensitivity, Specificity, PPV (TP FN) (TN FP) (TP FP). TN TP TN NPV, Accuracy (TN FN) (TN FN TP FP). FN % patients with unsuspected N2 disease 100. ((383 (FP TP)) Results Patient Characteristics and Overall Staging There were 383 patients (227 men) with primary nonsmall cell lung cancer. The patient characteristics for these patients are shown in Table 2. As shown in Figure 1, 184 of the 383 patients (48%) were clinically staged as N2 positive and 199 (52%) were staged as N2 negative. Eighty-seven patients were pathologically confirmed to have N2 disease, and 97 of the patients were found to be false positives on clinical staging modalities. Twentyeight patients (14%) had unsuspected N2 disease. Table 3 shows the efficacy of clinical staging based on FDG- PET/CT scans and CT scans stratified by stage. N2 Disease There were a total of 234 N2 positive lymph nodes in the 115 patients with N2 disease. Thirty-four of these lymph nodes were unsuspected in the 28 patients who had unsuspected N2 disease. Figure 2 shows the distribution of these nodes in the previously described 87 and 28 patients. The most common location is the subcarinal (7) lymph node (32% of all positive N2 nodes), followed by the paratracheal (4R) nodes (21% of all positive N2 nodes). N2 disease was confirmed by mediastinoscopy in 46 patients, by EUS-FNAs in 34, by transbronchial biopsy in 7, and by thoracotomy in 28. Unsuspected N2 disease was found in 28 patients (14%). Table 4 shows the N2 nodal distribution and histology of these patients based on the lobar location of the primary cancer. Table 5 shows that the most common location for unsuspected N2 disease. It was in the posterior mediastinal lymph nodes (those nodes accessible by EUS-FNA, 58% for the 12 patients clinically staged as I and 86% for the 14 patients clinically staged as II). The Table 2. Patient Characteristics (N 383) All Patients Median age in years (range) 68 (31 82) Gender Males 227 (59%) Females 156 (41%) Number of patients with pathologically 115 (30%) proven N2 disease Number of patients found to have unsuspected N2 disease at the time of resection 28 (24% of patients with N2) Pathological stage I 168 (44%) II 55 (14%) III 135 (35%) IV 25 (7%) Procedure/surgery a Lobectomy 206 (54%) Pneumonectomy 23 (6%) Segmentectomy 66 (17%) Mediastinoscopy 138 (36%) EUS 47 (12%) Histology Squamous cell carcinoma 167 (44%) Adenocarcinoma 144 (38%) Bronchoalveolar carcinoma 12 (3%) Neuroendocrine 9 (2%) Carcinoid 10 (3%) Other type nonsmall cell lung 41 (11%) cancer, mixed, or non-specified nonsmall cell lung cancer a Some patients had more than one procedure performed.

4 GENERAL THORACIC 1210 CERFOLIO ET AL Ann Thorac Surg IMPROVING CLINICAL STAGING OF NSCLC 2005;80: Fig 1. Patient stratification flow chart. (CT computed tomographic; NSCLC nonsmall cell lung cancer; PET-CT positron emission tomographic-computed tomographic.) sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of clinical staging by FDG- PET/CT for each nodal station is depicted in Table 6. Standard Uptake Value Figure 3 shows the median value and the range of the maxsuv for each N2 lymph nodes grouped by regions. It illustrates the considerable overlap between true positive and false positive values. Interestingly, the median maxsuv of the primary tumor in the lung for the 12 patients with clinically staged I disease who had unsuspected N2 disease was 8.1 compared with 3.7 for the other 128 patients clinically staged as I who were N2 negative (p 0.048). Similarly, the median maxsuv of the primary tumor in the lung for the 14 patients with clinically staged II disease who had unsuspected N2 disease was 9.5 compared with 5.0 for the other 36 patients clinically staged as II who were N2 negative (p 0.05). Comment Despite the addition of the FDG-PET scan and integrated scans, the clinical stage of patients with NSCLC only correctly predicts the actual stage (the positive predictive value) in approximately 50% of the patients. In addition, we found a relatively low accuracy for both and CT scan in this prospective study at each stage. Toloza and colleagues [14] in 2003 reported similar findings for CT scans. They found computed tomography to have a sensitivity of only 57% and a specificity of 82% for metastatic disease in the mediastinum despite improvements in CT scan resolution. In addition, computed tomography has been shown to have low negative and positive predictive values for direct tumor invasion into the chest wall or mediastinal structures (T3 and T4 involvement) [15]. The low accuracy of FDG-PET has been reported by us in two previous prospective trials [2, 16] as well as by Reed and colleagues [17] in a multi-institutional trial in The real question is how often does this inaccurate staging adversely affect patient care? The answer to that question depends partially on one s belief of what the best treatment of lung cancer is for each stage. In this study we found the clinical stage to be incorrect most often in patients with stage II (N1 disease). For now the standard of care for these patients is surgery. We believe that non-completed multi-institutional trials that are evaluating the use of Table 3. Efficacy of Clinical Staging Positive Predictive Value Sensitivity Negative Predicted Value Specificity Accuracy Stage I II III IV CT computed tomography; PET positron emission tomography.

5 Ann Thorac Surg CERFOLIO ET AL 2005;80: IMPROVING CLINICAL STAGING OF NSCLC Table 5. Number and Percent of the 28 Patients With Unsuspected N2 Disease and in the Posterior Mediastinal Lymph Nodes By Stage Clinical Stage by Number of Patients Unsuspected N2 Disease (%) 1211 Unsuspected N2 Disease in the Posterior Mediastinal Lymph Nodes GENERAL THORACIC Fig 2. The distribution of N2 disease by lymph node (LN) stations in the 115 patients. Some patients had N2 disease in more than one N2 location. One patient had unsuspected N2 disease in the station #1 lymph node not shown in this figure. neoadjuvant therapy for stage Ib and N1 stage II disease will show a benefit for preoperative chemotherapy or chemoradiotherapy in these patients. If these early (unpublished) data are proven true, this difference between clinical stage and pathologic stage will become even more important in the preoperative management of patients with NSCLC. The use of endobronchial ultrasound-guided transbronchial needle aspiration of N1 nodes may become a critical part of preoperative staging [18]. However, for now the standard of care for patients with N1 disease is surgery alone followed by adjuvant chemotherapy. Thus, only N2 or M1 disease will change the preoperative care. Most surgeons search carefully for M1 disease prior to surgery. The FDG-PET or is the standard of care for many of us, and in addition, some order brain magnetic resonance imaging and bone scans as a routine. Thus we are left with enhancing our ability to preoperatively diagnosis N2 disease as a means to improve treatment outcomes. In this study the most common locations for N2 disease were found to be the subcarinal (7) lymph node station and the lower right paratracheal (4R) station. The most common locations for unsuspected N2 disease were the subcarinal and aorta-pulmonary window stations. The N2 node that is involved may be dependent on the lobar location of the primary tumor, and this is a topic of future study for us, but in this report we do not have enough data for further analysis. I (8.6%) 7 (58%) II (28%) 12 (86%) III ( 1%) 1 IV 44 1 ( 1%) 1 Mediastinoscopy: Staging Upper and Lower Paratracheal Lymph Nodes Mediastinoscopy is a safe and accurate technique to prove or disprove metastatic NSCLC in the paratracheal (2R, 2L, 4R, and 4L lymph nodes). Although one can often get to the proximal or top part of the subcarinal lymph node by mediastinoscopy, the body of the node (where the vast majority of the cancer was discovered in this study) is not accessible by mediastinoscopy. EUS-FNA is the best method available to assess the entire subcarinal lymph node. Some physicians use it to biopsy the 4R as well, but we have not had that experience. There are many surgeons who perform mediastinoscopy on all patients who have NSCLC. If this had been our standard practice, we would have discovered unsuspected N2 disease in 5 of the 28 patients (assuming a 100% accuracy of mediastinoscopy at all paratracheal stations). However, a few physicians order EUS-FNA on all patients. The EUS-FNA: Staging Of Posterior Mediastinal Lymph Nodes EUS-FNA is the best way to obtain cytological confirmation from the 5, 7, 8, and 9 stations. Wallace and colleagues [19] in 2004 showed that 1 in 5 patients have unsuspected N2 disease in the EUS-FNA accessible posterior mediastinal lymph nodes. However, they Table 4. N2 Nodal Distribution and Histology of the 26 Patients Clinically Staged as Stage I or II With Unsuspected N2 Disease Based on the Lobar Location of the Primary Tumor Location of the Primary Nonsmall Cell Lung Cancer Right Upper Lobe Right Middle Lobe Right Lower Lobe Left Upper Lobe Left Lower Lobe Stage I II I II I II I II I II 2R, 4R ŒŒ 5, 6 Œ 7 Œ ŒŒ ¼ 8, 9 Œ¼ 1 patient had 2 nodes involved primary adenocarcinoma in RLL, node stations 2, 4, 7, 8, 9 (not shown in this chart). patient with adenocarcinoma; Œ patient with squamous cell carcinoma; ¼ patient with other type of NSCLC.

6 GENERAL THORACIC 1212 CERFOLIO ET AL Ann Thorac Surg IMPROVING CLINICAL STAGING OF NSCLC 2005;80: Table 6. Efficacy of the Scan for Each N2 Nodal Station a Stations Sensitivity (%) Specificity (%) Positive Predictive Value (%) Negative Predictive Value (%) Accuracy (%) 2R, 2L L, 4R , a Some patients had more than one N2 station positive. used CT scan only in that study, and patients did not undergo FDG-PET. Because we have shown EUS-FNA to be both safe and 97% accurate [7] and Savides and Perricone [8] in 2004 reported a similar accuracy of 98% for EUS-FNA for N2 nodes, the addition of EUS in all patients has the potential to significantly lower the incidence of unsuspected N2 disease. One limitation is that EUS-FNA is not available at all centers. Role of the MaxSUV of the Primary Nonsmall Lung Cancer A sub-analysis of the 12 patients clinically staged as I who had unsuspected N2 disease and the 14 patients staged as II who had N2 disease shows a greater incidence of adenocarcinoma as compared with other NSCLC types. Moreover, their median maxsuv was higher than those who were truly negative. Perhaps the maxsuv of the primary ( 10) may serve as a guide to help identify those patients who are at greater risk of N2 disease and for those patients who we should more carefully search for it (routine mediastinoscopy and EUS-FNA) prior to resection. We have shown that the maxsuv of the primary itself is a predictor of nodal involvement and survival [20]. Fig 3. The median maximum standard uptake value (maxsuv) (with range) of the mediastinal lymph node that were true positives (dashed darker line) and false positives (solid lighter line) grouped by lymph nodes stations. Role of the MaxSUV of the Mediastinal Lymph Nodes This is the first series to show the accuracy of the individual N2 lymph node stations for scans based on the maxsuv of each node. In two of our previous studies, one with 400 patients that evaluated dedicated PET [2] and the other with 129 patients that evaluated integrated PET/CT scans [2], we reported the efficacy at each lymph node station. The findings (accuracy) in those studies were remarkably similar to the results we found in this study. However, the likelihood of finding metastatic cancer in a node based on the maxsuv level for each node has never been reported. In this report we found that as the median maxsuv was higher in those patients with true positive nodes compared with those with false positive nodes. However, as seen in Figure 3, patients can have a maxsuv of greater than 12 in the 4R node, 9 in the 5 node, and 8 in the 7 node, and yet have benign nodes. Thus, false positives are not uncommon with very high maxsuv values. Therefore, histologic confirmation of any suspicious mediastinal lymph node is absolutely mandatory, and treatment decisions can not be made based on the maxsuv on scans alone. In conclusion, we have shown that the clinical stage, despite the use of integrated scans differs from the pathologic stage in many patients, especially in those with predicted early staged NSCLC. The most common location for N2 disease is the subcarinal lymph node and the lower right paratracheal lymph node. The most common location for unsuspected N2 disease occurs in the posterior mediastinal lymph nodes, especially the subcarinal area. This may be dependent on the lobar location of the primary. Because EUS-FNA has been shown to be a safe, minimally invasive, and accurate technique to biopsy these posterior mediastinal lymph nodes, we suggest it be considered as a routine staging procedure for patients who are clinically staged as I or II or for those with a high maxsuv of the primary, or for both. A prospective trial is needed to evaluate the role of routine EUS-FNA and mediastinoscopy in patients that have scans and CT scans that are normal for mediastinal nodes. This prospective trial has already been approved by the institutional review board at the

7 Ann Thorac Surg CERFOLIO ET AL 2005;80: IMPROVING CLINICAL STAGING OF NSCLC University of Alabama at Birmingham and is well underway at our institution. References 1. Ihde DC, Minna JD. Non-small cell lung cancer: part I. Biology, diagnosis and staging. Curr Probl Cancer 1991;15: Cerfolio RJ, Buddhiwardhan O, Bryant AS, et al. The accuracy of integrated PET/CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg 2004;78: Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual modality PET/CT in preoperative staging. Radiology 2003;229: Lardinois D, Weder W, Hany TF, et al. Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 2003;348: Aquino SL, Asmuth JC, Alpert NM, et al. Improved radiologic staging of lung cancer with 2-[18]-flouro-2-deoxy-Dglucose-positron emission tomography and computed tomography registration. J Comput Assist Tomogr 2003;27: Hawes RH, Gress F, Kesler KA, Cummings OW, Conces DJ, Jr. Endoscopic ultrasound versus computed tomography in the evaluation of the mediastinum in patients with nonsmall-cell lung cancer. Endoscopy 1994;26: Eloubeidi MA, Cerfolio RJ, Chen VK, et al. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph nodes in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 2005;79: Savides TJ, Perricone A. Impact of EUS-guided FNA of enlarged mediastinal lymph nodes on subsequent thoracic surgery rates. Gasterointest Endosc 2004;60: Mountain CF. Revisions in the International Systems for Staging Lung Cancer. Chest 1997;111: Nabi HA, Zubeldia JM. Clinical applications of F18-FDG in oncology. J Nucl Med Technol 2002;30: Catalano MF, Sivak MV, Rice T, Gragg LA, Van Dam J. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc 1994;40: Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med 1997;127: Beck J. Likelihood ratios: another enhancement of sensitivity and specificity. Arch Pathol Lab Med 1986;110: Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123:137S 46S. 15. Detterbeck FC, Jones DR, Parker LA. Intrathoracic staging. In: Detterbeck FC, Rivera PM, Socinski MA, et al. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: Saunders, 2001; Cerfolio RJ, Ohja B, Bryant AS, et al. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003;76; Reed CM, Posther KE, Woolson SL, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thor Cardiovasc Surg 2003;126: Yasufuku K, Chiyo M, Sekine Y, et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004;126: Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg 2004;77: Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values (SUV) on pet of a non-small cell lung cancer predicts stage, recurrence and survival. J Thor Cardiovasc Surg 2005 (publication pending). GENERAL THORACIC DISCUSSION DR JOHN R. ROBERTS (Nashville, TN): Rob, that s an excellent work and I really think that you ve shed some light on some of the difficulty of those of us who are working in the histoplasmosis belt and how positron emission tomographic (PET) scans are not nearly as accurate as they are for perhaps the rest of the country. The main question I had is that you are supporting using endoscopic ultrasound (EUS) for those stations. You could also use thoracoscopy, especially in those patients that you ve already put to sleep for a mediastinoscopy, and it would allow you to identify pleural mets and some other findings that you can t pick up on EUS. I wondered if you would comment about the possible use of that modality. DR CERFOLIO: That is a good point and of course we do video-assisted thoracoscopic surgery (VATS) as well. I told you EUS-fine-needle aspiration (FNA) is probably best for the No. 7, but thoracoscopy has a lot of advantages of stages, but not just for some nodes for other areas as well. You re able to look at a pleural space to rule out M1 implants if there s a fluid collection, you re able to tap it and maybe get more accurate cytology than thoracentesis allows, as we have published in an article last year in Chest. It also allows you to better assess the T, tumor status, as T2 or T3, although that rarely changes what we re going to do. We also didn t mention Wang needle biopsy, which is another way to get to No. 7 s, but it doesn t get to 8 or 9. So I think if you are going to be doing a general anesthetic for mediastinoscopy, it may make sense, in some patients, to go ahead and do a thoracoscopy, although there s added time in the OR and added expense and more incisions. Plus some nodes are more difficult to assess because the tumor is in the way and then the VATS is more involved. EUS-FNA, which does not require a general anesthetic or any incisions, I think gives you a bigger bang for your buck because you re able to look at more stations with less invasiveness and cost. DR DAVID H. HARPOLE, JR (Durham, NC): That s a very nice review of your continued prospective data collection. I just have a couple of questions. First of all, in your mediastinoscopy, obviously the level 5 nodes were certainly involved and suspicious in a lot of cases. Do you do an extended mediastinoscopy or an anterior mediastinoscopy on patients with left upper lobe lesions to evaluate those? Secondly, obviously the Japanese have written a lot about this, but you have a pretty good data set here. Can you use this collection of information to kind of give us a better prediction for right upper lobe, where you would want to look first, and left upper lobe, where do you want to look first? I think that s where this will have real value. I would be a little surprised if an apical right lung lesion would map down to the level 9 lymph node occasionally, but you would certainly have information to guide us.

8 GENERAL THORACIC 1214 CERFOLIO ET AL Ann Thorac Surg IMPROVING CLINICAL STAGING OF NSCLC 2005;80: DR CERFOLIO: Thanks Dave, those are great points. We didn t want to throw in too much data into one paper and we always tried to stay focused and answer one specific question at a time, but certainly we have mapped out the distribution of the lymph nodes based on the location of the primary tumor. And you re right, that right upper lobe tumor is going to metastasize to a 4R much more commonly than an 8 or 9. So for that patient we would recommend a mediastinoscopy over an EUS. That s part of the cost analysis that we are studying and hope to deliver in a few years. As for your other question about extended mediastinoscopy the short answer is no I do not do it. I m chicken, or as I prefer to think about it I am smart. I think that mediastinoscopy is the most dangerous operation I do and certainly the most dangerous operation I teach, and so I do not do any extended mediastinoscopy. DR HARPOLE: Or Chamberlains? DR CERFOLIO: Left VATS has supplanted Chamberlain in my practice for the 5 and 6 station. I rarely if ever do a Chamberlain now. As discussed before, I do left VATS to look at the pleura, assess the tumor, and I can most times get to the 5 and especially the 6 nodes very well. Of course, there is a controversy about those nodes acting like N1 nodes in LUL tumors as well we treat them as N2. DR FRANK C. DETTERBECK (Chapel Hill, NC): I certainly enjoyed your presentation. I think we need to be sophisticated in how we interpret the data. If you look at PET scanning for distant disease, I think there are a lot of studies that show that if you have a clinical stage I tumor, the chance you re going to actually find distant disease that is a met is less than 5% with PET, whereas if you have clinical stage III disease, you have about a 25% to 30% chance of finding it. You didn t really give us that number, but I would be curious as to what it was in your experience, how often you found distant disease. I also think the same applies for intrathoracic staging if you have central tumors or if you have an N1 tumor. We ve got lots of data based on computed tomography (CT) that you have about a 25% to 30% chance of finding unsuspected mets. You found the same thing with PET. We ve sort of looked at PET as being the answer, but we ve never really looked at it with subsets of patients. So I think it s great that you reported at least that one subset, and I would encourage you to report further subsets, central versus peripheral tumors, to help us get a better idea about PET. Finally, a word of caution: Although you are recommending EUS, it is really EUS in the face of having done a mediastinoscopy for many of your patients, so that the unsuspected disease was there because we already did a mediastinoscopy in the other locations. And the other thing about EUS is that although the data for EUS suggests that it is a very accurate test, still in most of the centers the EUS is done for enlarged nodes and most of the data that s out there is for enlarged nodes, and whether we re going to be just as accurate in ruling out N2 disease in these unsuspected areas when the nodes are not enlarged I think is not quite as clear, and so I d be curious to hear your thoughts about that. DR CERFOLIO: You have raised many excellent points and I ll briefly answer them. I ll group your first two questions and answer them in one. The first two questions were about trying to look at risk factors for peripheral lesions and looking at the role of PET for clinically staged I patients. We have a very important paper coming out in the Journal of CTVS in March or April of this year that shows that the maxsuv of the primary tumor on FDG-PET is a more important predictor of pathologic stage, recurrence and survival than the current TNM staging classification so that value may be a more important preoperative factor than whether it is peripheral, whether it s central, whether it s adeno, whether it s squamous. It tells you the biological aggressiveness of a tumor in a host, and it doesn t get better than that. So I think when I have a high maxsuv, in our paper it was greater than 10, even if the patient is clinically staged I and small and peripheral, you better look for M1 disease, because you re more likely to find it. So I disagree with your point somewhat and that 5% you quoted might not be applicable to a subset of patients with clinically stage I disease. The last point is really that EUS-FNA does not replace mediastinoscopy and we categorically agree it does not assess the paratracheal nodes well. Mediastinoscopy should still be performed, and the question is should EUS be performed routinely as well. There is a study quoted in our paper that shows that EUS may have a role in patients with normal sized nodes by CT, but PET was not used in that paper they found unsuspected N2 disease in 1 in 5 patients in that study. And there s a learning curve. We ve sent over 900 patients for EUS. You have to have an experienced guy. The only way to get experience is to start sending him cases. Finally, the real future we think, may lie in ultrasound-guided transbronchial biopsies of N1 and N2 nodes. DR MALCOLM M. DECAMP (Boston, MA): Great series. I have a specific technical question. You did lymphadenectomy to confirm the positive predictive value of these. I have a specific question about left upper lobe tumors and how you re getting L2 and L4 after doing a left upper lobectomy so that you really have a handle on the occult metastatic disease for that particular subgroup of patients. DR CERFOLIO: Mack, that s a great question and you are right we do not get the 2L s via left thoracotomy. The only way to get them is via mediastinoscopy. But the 4L s I really do get in most all patients, except for obese ones. DR JACK A. ROTH (Houston, TX): A high percentage of your patients underwent mediastinoscopy. How often did you uncover occult N3 disease in these patients? DR CERFOLIO: I do not have that number I will have to go back and look at the stats but it is not that common, I would say only about 5%.

Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung Cancer

Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung Cancer Maximum Standard Uptake Value of Mediastinal Lymph odes on Integrated FDG-PET-CT Predicts Pathology in Patients with on-small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Robert J. Cerfolio, MD, FACS,

More information

The maximum standardized uptake value (maxsuv) on

The maximum standardized uptake value (maxsuv) on Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall- Cell Lung

More information

MEDIASTINAL STAGING surgical pro

MEDIASTINAL STAGING surgical pro MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical

More information

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer

Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Patients with stage IIIa non-small cell lung cancer

Patients with stage IIIa non-small cell lung cancer GENERAL THORACIC When is it Best to Repeat a 2-Fluoro-2-Deoxy-D- Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant

More information

Non-small cell lung cancer (NSCLC) accounts for

Non-small cell lung cancer (NSCLC) accounts for Survival of Patients With True Pathologic Stage I Non-Small Cell Lung Cancer Robert J. Cerfolio, MD, and Ayesha S. Bryant, MSPH, MD Division of Cardiothoracic Surgery, University of Alabama at Birmingham,

More information

Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)

Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:

More information

PET/CT in lung cancer

PET/CT in lung cancer PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of

More information

Endoscopic Ultrasound and Positron Emission Tomography for Lung Cancer Staging

Endoscopic Ultrasound and Positron Emission Tomography for Lung Cancer Staging CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:846 851 Endoscopic Ultrasound and Positron Emission Tomography for Lung Cancer Staging MANDEEP S. SAWHNEY,*, ROBERT A. KRATZKE, FRANK A. LEDERLE, AMY M.

More information

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.

More information

In 1982 Pearson and colleagues [1] from Toronto published

In 1982 Pearson and colleagues [1] from Toronto published Transition From Mediastinoscopy to Endoscopic Ultrasound for Lung Cancer Staging Mark I. Block, MD Division of Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida Background. Esophageal endoscopic

More information

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS

More information

Endoscopic Ultrasound-Guided Fine- Needle Aspiration for Non-small Cell Lung Cancer Staging* A Systematic Review and Metaanalysis

Endoscopic Ultrasound-Guided Fine- Needle Aspiration for Non-small Cell Lung Cancer Staging* A Systematic Review and Metaanalysis CHEST Endoscopic Ultrasound-Guided Fine- Needle Aspiration for Non-small Cell Lung Cancer Staging* A Systematic Review and Metaanalysis Carlos G. Micames, MD; Douglas C. McCrory, MD; Darren A. Pavey, MD;

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Patients with pathologically diagnosed involved mediastinal

Patients with pathologically diagnosed involved mediastinal MINI-SYMPOSIUM ON EMERGING TECHNIQUES FOR LUNG CANCER STAGING European Trends in Preoperative and Intraoperative Nodal Staging: ESTS Guidelines P. De Leyn, MF, PhD,* D. Lardinois, MD, P. Van Schil, MD,

More information

Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Non-Small Cell Lung Cancer and Prior Negative Mediastinoscopy

Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Non-Small Cell Lung Cancer and Prior Negative Mediastinoscopy Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Non-Small Cell Lung Cancer and Prior Negative Mediastinoscopy Mohamad A. Eloubeidi, MD, MHS, Ashutosh Tamhane, MD, MSPH, Victor K. Chen,

More information

Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer

Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

S taging non-small lung cancer (NSCLC) is an important

S taging non-small lung cancer (NSCLC) is an important 696 LUNG CANCER Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study K G Tournoy, S Maddens, R Gosselin, G

More information

GTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 605

GTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 605 Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders Robert J. Cerfolio, MD, FACS,

More information

Minimally Invasive Mediastinal Staging of Non Small-Cell Lung Cancer: Emphasis on Ultrasonography-Guided Fine-Needle Aspiration

Minimally Invasive Mediastinal Staging of Non Small-Cell Lung Cancer: Emphasis on Ultrasonography-Guided Fine-Needle Aspiration Endobronchial ultrasound and endoscopic ultrasound-guided lymph node biopsy may represent an alternative to cervical mediastinoscopy. Dorothy Fox, Rough Seas. Acrylic on canvas, 36ʺ 36ʺ. Minimally Invasive

More information

Accurate mediastinal staging is a critical component

Accurate mediastinal staging is a critical component Endobronchial Ultrasound for Lung Cancer Staging: How Many Stations Should Be Sampled? Mark I. Block, MD Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida Background. No guidelines exist

More information

Endoscopic ultrasound-guided needle aspiration in lung cancer

Endoscopic ultrasound-guided needle aspiration in lung cancer ORIGINAL ARTICLE Artur Szlubowski 1, Marcin Zieliński 1, Joanna Figura 1, Jolanta Hauer 1, Witold Sośnicki 1, Juliusz Pankowski 2, Anna Obrochta 2, Magdalena Jakubiak 2 1 Department of Thoracic Surgery

More information

Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging Patients With Carcinoma of the Lung

Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging Patients With Carcinoma of the Lung Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging Patients With Carcinoma of the Lung Michael B. Wallace, MD, MPH, Gerard A. Silvestri, MD, MS, Anand V. Sahai, MD, MS (Epid), Robert H. Hawes,

More information

Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer

Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Robert J. Cerfolio, MD, Ayesha S. Bryant, MSPH, Thomas S. Winokur, MD, Buddhiwardhan

More information

Endoscopic and Endobronchial Ultrasound Staging for Lung Cancer. Michael B. Wallace, MD, MPH Professor of Medicine Mayo Clinic, Jacksonville

Endoscopic and Endobronchial Ultrasound Staging for Lung Cancer. Michael B. Wallace, MD, MPH Professor of Medicine Mayo Clinic, Jacksonville Endoscopic and Endobronchial Ultrasound Staging for Lung Cancer Michael B. Wallace, MD, MPH Professor of Medicine Mayo Clinic, Jacksonville Background: Lung Cancer 170,000 cases/yr in U.S. (# 1 cancer)

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Approximately 14,000 persons are given diagnoses of esophageal cancer each

Approximately 14,000 persons are given diagnoses of esophageal cancer each General Thoracic Surgery Cerfolio et al The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography

More information

Utility of endobronchial ultrasound guided mediastinal lymph node biopsy in patients with non small cell lung cancer

Utility of endobronchial ultrasound guided mediastinal lymph node biopsy in patients with non small cell lung cancer GENERAL THORACIC SURGERY Utility of endobronchial ultrasound guided mediastinal lymph node biopsy in patients with non small cell lung cancer Benjamin E. Lee, MD, a,b Elaine Kletsman, PA, a,b John R. Rutledge,

More information

The currently used standard cervical mediastinoscopy (SCM)

The currently used standard cervical mediastinoscopy (SCM) ORIGINAL ARTICLE The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission Tomography and Computed Tomography

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Adam J. Hansen, MD UHC Thoracic Surgery

Adam J. Hansen, MD UHC Thoracic Surgery Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered

More information

Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer

Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer Department of Thoracic Oncology, National Cancer Centre Hospital East, Chiba, Japan Correspondence to: Dr T Hishida, Department of Thoracic Oncology, National Cancer Centre Hospital East, 6-5-1, Kashiwanoha,

More information

PET CT for Staging Lung Cancer

PET CT for Staging Lung Cancer PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct

More information

Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer

Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Original Article on Transbronchial Needle Aspiration (TBNA) Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Xu-Ru Jin 1 *, Min

More information

The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL

The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL Conflict of Interest This presentation is supported by AstraZeneca Two main steps before

More information

Video-Mediastinoscopy Thoracoscopy (VATS)

Video-Mediastinoscopy Thoracoscopy (VATS) Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin

More information

Do we need a new SUVmax threshold value for the evaluation of mediastinal lymph nodes?

Do we need a new SUVmax threshold value for the evaluation of mediastinal lymph nodes? Current Thoracic Surgery To cite this article: Yıldız ÖÖ, Özkan S, Temiz G, Gülyüz OC, Karaoğlanoğlu N. Do we need a new SUVmax threshold value for the evaluation of mediastinal lymph nodes? Curr Thorac

More information

Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?

Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Benjamin D. Kozower, MD, Bryan F. Meyers, MD, Carolyn E. Reed, MD, David R. Jones, MD, Paul

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Accepted Manuscript. Indications for Invasive Mediastinal Staging for Non-small Cell Lung Cancer. Jules Lin, MD, Felix Fernandez, MD

Accepted Manuscript. Indications for Invasive Mediastinal Staging for Non-small Cell Lung Cancer. Jules Lin, MD, Felix Fernandez, MD Accepted Manuscript Indications for Invasive Mediastinal Staging for Non-small Cell Lung Cancer Jules Lin, MD, Felix Fernandez, MD PII: S0022-5223(18)31872-5 DOI: 10.1016/j.jtcvs.2018.07.027 Reference:

More information

GUIDELINE RECOMMENDATIONS

GUIDELINE RECOMMENDATIONS European Journal of Cardio-Thoracic Surgery 48 (2015) 1 15 doi:10.1093/ejcts/ezv194 Cite this article as: Vilmann P, Frost Clementsen P, Colella S, Siemsen M, De Leyn P, Dumonceau J-M et al. Combined endobronchial

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Role of EBUS in mediastinal staging of lung cancer. -Dr. Nandakishore Baikunje

Role of EBUS in mediastinal staging of lung cancer. -Dr. Nandakishore Baikunje Role of EBUS in mediastinal staging of lung cancer -Dr. Nandakishore Baikunje Overview of the seminar Introduction Endosonography to stage the mediastinum Technical aspects of EBUS-TBNA for mediastinal

More information

Video-assisted thoracoscopic surgery in lung cancer staging

Video-assisted thoracoscopic surgery in lung cancer staging Review Article on Thoracic Surgery Page 1 of 7 Video-assisted thoracoscopic surgery in lung cancer staging Frederico Krieger Martins, Guilherme Augusto Oliveira, Juliano Cé Coelho, Márcio Chmelnitsky Kruter,

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Les techniques invasives et minimalement invasives dans le staging du cancer bronchopulmonaire. V. Ninane, Hôpital Saint-Pierre, Bruxelles, Belgique

Les techniques invasives et minimalement invasives dans le staging du cancer bronchopulmonaire. V. Ninane, Hôpital Saint-Pierre, Bruxelles, Belgique Les techniques invasives et minimalement invasives dans le staging du cancer bronchopulmonaire V. Ninane, Hôpital Saint-Pierre, Bruxelles, Belgique 1 Invasive Mediastinal Staging Purpose : to exclude Involvement

More information

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Charles Mulligan, MD, FACS, FCCP 26 March 2015 Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening

More information

Recommendations 1 For mediastinal nodal staging in patients with suspected or proven non-small-cell lung cancer

Recommendations 1 For mediastinal nodal staging in patients with suspected or proven non-small-cell lung cancer Guideline 545 Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal

More information

Thoracic Surgery; An Overview

Thoracic Surgery; An Overview Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease

More information

EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients

EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients ORIGINAL ARTICLE LUNG IMAGING EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients Juliana Guarize 1, Monica Casiraghi 1, Stefano Donghi 1, Chiara Casadio 2, Cristina Diotti 1, Niccolò

More information

Key words: CT scan; endobronchial ultrasound; integrated PET; lung cancer; staging

Key words: CT scan; endobronchial ultrasound; integrated PET; lung cancer; staging CHEST Original Research INTERVENTIONAL PULMONOLOGY Application of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Following Integrated PET/CT in Mediastinal Staging of Potentially Operable

More information

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma. Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest

More information

Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer

Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph

More information

Felix J. F. Herth, MD, FCCP; Ralf Eberhardt, MD; Mark Krasnik, MD; and Armin Ernst, MD, FCCP

Felix J. F. Herth, MD, FCCP; Ralf Eberhardt, MD; Mark Krasnik, MD; and Armin Ernst, MD, FCCP Original Research INTERVENTIONAL PULMONOLOGY Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of Lymph Nodes in the Radiologically and Positron Emission Tomography-Normal Mediastinum in

More information

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017 Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial

More information

PET/CT Frequently Asked Questions

PET/CT Frequently Asked Questions PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake

More information

Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer

Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer TASK FORCE REPORT ESGE/ERS/ESTS GUIDELINES Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer European Society of Gastrointestinal Endoscopy (ESGE) Guideline,

More information

Surgical management of lung cancer

Surgical management of lung cancer Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

The Role of PET / CT in Lung Cancer Staging

The Role of PET / CT in Lung Cancer Staging July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year

More information

CT PET SCANNING for GIT Malignancies A clinician s perspective

CT PET SCANNING for GIT Malignancies A clinician s perspective CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset

More information

Radiology Pathology Conference

Radiology Pathology Conference Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

VAMLA/TEMLA. Todd L. Demmy

VAMLA/TEMLA. Todd L. Demmy VAMLA/TEMLA Todd L. Demmy Disclosures/ Questions Objectives - Staging Learn new lymphadenectomy (LA) results: Video-Assisted Mediastinal (VAMLA) Transcervical Extended Mediastinal (TEMLA) Compare with

More information

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department

More information

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin

More information

Bronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer

Bronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer FRANCISCO AÉCIO ALMEIDA, MD, MS, FCCP Associate Staff Member, Director, Interventional Pulmonary Medicine Fellowship Program, Respiratory Institute, Cleveland Clinic, Cleveland, OH Bronchoscopy and endobronchial

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Innovations in Lung Cancer Diagnosis and Surgical Treatment

Innovations in Lung Cancer Diagnosis and Surgical Treatment Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Rigshospitalet, Copenhagen, Denmark.

Rigshospitalet, Copenhagen, Denmark. Current Health Sciences Journal Vol. 35, No. 1, 2009 Original Paper A Comparison of Endoscopic Ultrasound Guided Biopsy and Positron Emission Tomography with Integrated Computed Tomography in Lung Cancer

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

Lung Cancer 69 (2010) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:

Lung Cancer 69 (2010) Contents lists available at ScienceDirect. Lung Cancer. journal homepage: Lung Cancer 69 (2010) 60 65 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan EUS-FNA in the preoperative staging of non-small cell lung cancer M.

More information

Diagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis)

Diagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis) Diagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis) Sevda Sener Cömert, MD, FCCP. SBU, Kartal Dr.Lütfi Kırdar Training and Research Hospital Department of Pulmonary

More information

Bilateral hilar 18 F-FDG avid foci are often noted on

Bilateral hilar 18 F-FDG avid foci are often noted on Bilateral Hilar Foci on F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology Maroun Karam 1, Shayna Roberts-Klein 1, Narendra Shet 2, Johanna Chang 2,

More information

Positron Emission Tomography in Lung Cancer

Positron Emission Tomography in Lung Cancer May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and

More information

Pneumonectomy After Induction Rx: Is it Safe?

Pneumonectomy After Induction Rx: Is it Safe? Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction

More information

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED

More information

Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index

Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index doi: 10.5761/atcs.oa.14-00241 Original Article Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index Satoshi Shiono, MD, 1 Naoki Yanagawa, MD, 2 Masami Abiko,

More information

18F-FDG Positron Emission Tomography CT (FDG PET-CT) in the Management of Pancreatic Cancer: Initial Experience in 12 Patients

18F-FDG Positron Emission Tomography CT (FDG PET-CT) in the Management of Pancreatic Cancer: Initial Experience in 12 Patients 18F-FDG Positron Emission Tomography CT (FDG PET-CT) in the Management of Pancreatic Cancer: Initial Experience in 12 Patients Muhammad Wasif Saif 1, Daniel Cornfeld 1, Houmayoun Modarresifar 2, Buddhiwardhan

More information

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung

More information

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Educational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach.

Educational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach Robert A. Meguid, MD, MPH, FACS Assistant Professor of Cardiothoracic Surgery Surgical Director, Surgical

More information

Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis

Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis 1 Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis Optimal management of Cancer Histological diagnosis & accurate staging at presentation Molecular analysis of primary tumour

More information

Lung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) EBUS

Lung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) EBUS Lung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) Arvind Perathur Winter Retreat Feb 13 th 2011 Mason City IA 50401 EBUS Tiger now offers a very economical and environmentally friendly all electric

More information

PET/CT depiction of ATS mediastinal nodal stations: What every radiologist should know - diagnostic strategies and potential pitfalls

PET/CT depiction of ATS mediastinal nodal stations: What every radiologist should know - diagnostic strategies and potential pitfalls PET/CT depiction of ATS mediastinal nodal stations: What every radiologist should know - diagnostic strategies and potential pitfalls Poster No.: C-236 Congress: ECR 2009 Type: Educational Exhibit Topic:

More information

Lung Cancer Update. Disclosures. None

Lung Cancer Update. Disclosures. None Lung Cancer Update Ronald J Servi DO FCCP Adjunct Assistant Professor Department of Pulmonary Medicine University of Texas MD Anderson Cancer Center Banner MD Anderson Cancer Center Gilbert, Arizona Disclosures

More information

Invasive Mediastinal Staging of Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)

Invasive Mediastinal Staging of Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Invasive Mediastinal Staging of Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Frank C. Detterbeck, MD,

More information

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced

More information

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical

More information

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy) No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis

More information

Chirurgie beim oligo-metastatischen NSCLC

Chirurgie beim oligo-metastatischen NSCLC 24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital

More information

RESEARCH. 145 February 2015, Vol. 105, No. 2

RESEARCH. 145 February 2015, Vol. 105, No. 2 Integrated positron emission tomography/computed tomography for evaluation of mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosisendemic area: A 5-year prospective observational

More information

The current tumor-node-metastasis (TNM) staging

The current tumor-node-metastasis (TNM) staging CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:573 579 Influence of the Number of Malignant Regional Lymph Nodes Detected by Endoscopic Ultrasonography on Survival Stratification in Esophageal Adenocarcinoma

More information

Endoscopic UltraSound (EUS) Endoscopic Mucosal Resection (EMR) Moishe Liberman Director C.E.T.O.C.

Endoscopic UltraSound (EUS) Endoscopic Mucosal Resection (EMR) Moishe Liberman Director C.E.T.O.C. Endoscopic UltraSound (EUS) Endoscopic Mucosal Resection (EMR) Moishe Liberman Director C.E.T.O.C. Division of Thoracic Surgery Centre Hospitalier de l Université de Montréal Research Grants: Disclosures

More information

FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer.

FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer. FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer. Schmidt-Hansen, M; Baldwin, DR; Zamora, J 2018 American Medical Association. All Rights Reserved.

More information